全球血栓彈力圖市場

預計到 2030 年全球血栓彈力圖市場規模將達到 9.331 億美元

全球血栓彈力圖市場規模預計在2024年為6.721億美元，預計2030年將達到9.331億美元，2024年至2030年的複合年成長率為5.6%。標準血栓彈力圖是本報告分析的細分市場之一，預計其複合年成長率為7.3%，到分析期結束時規模將達到2.824億美元。快速血栓彈力圖細分市場在分析期間的複合年成長率預計為4.2%。

美國市場規模估計為 1.831 億美元，中國市場預期複合年成長率為 9.2%

美國血栓彈力圖市場規模預計2024年達到1.831億美元。作為世界第二大經濟體，中國市場規模預計將在2030年達到1.91億美元，在2024-2030年的分析期間內，複合年成長率為9.2%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為2.6%和5.6%。在歐洲，德國市場的複合年成長率預計為3.7%。

全球血栓彈力圖市場—主要趨勢與促進因素摘要

血栓彈力圖如何重新定義重症加護中的止血測試？

血栓彈力圖 (TEG) 超越了傳統的凝血檢測，能夠動態地即時評估整個凝血過程，徹底改變了臨床醫生評估止血的方式。與 PT、aPTT 和 INR 等評估凝血連鎖中孤立點的傳統測試不同，TEG 全面評估血塊的形成、穩定和溶解。這種即時評估在創傷、心血管手術、肝臟移植和加護治療環境中特別有用，在這些環境中，快速、準確的血液製品給藥決策可以挽救生命。透過追蹤血液凝結時的黏彈性，TEG 可以幫助臨床醫生確定出血是由於血小板功能障礙、纖維蛋白原缺乏還是纖溶亢進引起的。其結果是製定個人化的輸血策略，減少不必要的血小板、血漿和冷沉澱物的使用，同時改善患者的預後。隨著人們對輸血相關併發症（如 TRALI 和免疫調節障礙）風險的認知不斷提高，醫院開始採用更準確、更有針對性的凝血監測，而 TEG 系統正在成為轉向針對患者的止血治療的領先技術。

血栓彈力圖能否成為外科手術和急診醫學的新標準？

血栓彈力圖的臨床多功能性使其成為外科和急診醫學的新護理標準，在這些領域出血併發症很常見，時間敏感的決策至關重要。在心臟和肝臟手術中，凝血障礙通常很複雜且由多種因素引起，TEG 提供了區分消耗性凝血病和稀釋性凝血病所需的粒度，從而可以進行有針對性的干涉。 TEG 在管理接受抗凝血治療的患者（無論是使用Warfarin、DOAC 或肝素）中的效用使其成為術前篩檢和術中監測的寶貴工具。急診室也在利用 TEG 管理創傷患者，其中大量輸血方案已根據 TEG 見解進行了最佳化，從而降低了發病率和死亡率。產科中心正在使用 TEG 來評估產後出血的出血風險，尤其是在妊娠毒血症和 HELLP 症候群病例中。同時，加護病房(ICU) 正在將 TEG 納入膿毒症、瀰漫性血管內凝血 (DIC) 和 COVID-19 相關凝血病患者的持續凝血功能評估中。 TEG 在各醫學學科的廣泛應用以及對快速數據驅動決策的需求，正在推動人們轉向使用 TEG 進行即時凝血診斷。

哪些技術進步正在擴展血栓彈力圖的功能？

血栓彈力圖技術的最新進展使系統更加方便用戶使用、準確且能適應各種臨床環境。現代 TEG 分析儀具有自動樣本處理、觸控螢幕介面和整合品管等功能，可減少技術人員的錯誤並確保結果的一致性。可攜式和照護現場(POC) TEG 系統正在擴大即時凝血監測的覆蓋範圍，不僅涵蓋三級醫院，也涵蓋小型外科中心、救護車和方艙醫院。軟體升級可實現高級分析、雲端基礎的數據共用以及與電子健康記錄(EHR) 的整合，以便快速解釋結果並有效用於多學科護理。還有基於墨盒的測試系統，無需手動移液並可在感染疾病爆發期間提高生物安全性。製造商也在探索多重檢測和生物標記整合，以提高診斷特異性並指導抗凝血逆轉策略。結合臨床培訓的加強和基於演算法的決策支援工具，這些增強功能正在降低學習曲線，並幫助臨床醫生將 TEG 見解納入即時治療決策中，從而擴大其在日益多樣化的醫療保健環境中的效用。

血栓彈力圖市場的成長受到多種因素的推動。

血栓彈力圖 (TEG) 的應用日益廣泛，主要原因是其在高風險手術、創傷護理和重症患者監護中的臨床相關性日益增強。全球心血管疾病、肝病和創傷的負擔日益加重（尤其是在新興國家），需要更精確的工具進行止血評估和輸血管理。此外，手術量的增加和微創手術的複雜性也推動了對精確術中凝血監測的需求。醫院面臨著減少血液製品使用量的壓力，以控制成本並避免輸血相關併發症，這推動了對精準引導輸血策略的需求，例如由血栓彈力圖 (TEG) 實現的策略。同時，老齡化人口中抗凝血治療和複雜凝血障礙的日益普及，使得對能夠即時準確評估凝血狀態的技術的需求也隨之增加。就地檢驗和診斷服務分散化的趨勢也使得 TEG 的應用範圍從大型醫院擴展到門診手術中心和重症監護病房。自動化、便攜性和 EHR 整合等技術進步正在提高易用性並減少操作障礙。同時，監管部門的核准和臨床指南的核准也正在強化 TEG 在現代臨床工作流程中的價值。這些動態在技術、醫療服務和患者人口統計領域的融合，正在推動全球血栓彈力圖市場的快速成長。

部分

類型（標準、快速 TEG、天然 TEG、肝素酶、功能性纖維蛋白原、血小板映射）、應用（心肺體外迴圈、肝臟手術、創傷手術、產科）、最終用戶（醫院、血庫、學術機構、其他最終用戶）

受訪公司範例（總合42家）

• 5-Diagnostics GmbH
• Bio-Zircon
• Biomart
• Chongqing Dingrun
• Chongqing Nanfang
• Diagnostica Stago
• Framar Hemologix Srl
• Guizhou Jinjiu Biotech
• Haemonetics Corporation
• HemaCore LLC
• Instrumentation Laboratory（Werfen）
• Lepu Medical Technology
• Medcaptain Medical Technology
• Medirox AB
• Render Biotech Co., Ltd.
• Sienco, Inc.
• SYCOmed eK
• Ud-Bio
• WerfenLife
• WITEYE

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶也將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 比賽

Global Thromboelastography Market to Reach US$933.1 Million by 2030

The global market for Thromboelastography estimated at US$672.1 Million in the year 2024, is expected to reach US$933.1 Million by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Standard Thromboelastography, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$282.4 Million by the end of the analysis period. Growth in the Rapid TEG segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$183.1 Million While China is Forecast to Grow at 9.2% CAGR

The Thromboelastography market in the U.S. is estimated at US$183.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$191.0 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global "Thromboelastography" Market - Key Trends & Drivers Summarized

How Is Thromboelastography Redefining Hemostasis Testing in Critical Care?

Thromboelastography (TEG) is revolutionizing how clinicians assess hemostasis, moving beyond traditional coagulation assays by providing a dynamic, real-time evaluation of the entire clotting process. Unlike conventional lab tests such as PT, aPTT, or INR, which assess isolated points of the coagulation cascade, TEG offers a comprehensive view of clot formation, stabilization, and dissolution. This real-time assessment is especially valuable in trauma, cardiac surgery, liver transplantation, and intensive care settings, where rapid and accurate decisions about blood product administration can be life-saving. By tracking the viscoelastic properties of blood as it clots, TEG enables clinicians to pinpoint whether bleeding is due to platelet dysfunction, fibrinogen deficiency, or hyperfibrinolysis. The result is a personalized transfusion strategy that reduces unnecessary use of platelets, plasma, and cryoprecipitate, while improving patient outcomes. Increasing awareness of the risks of transfusion-related complications-such as TRALI and immunomodulation-is pushing hospitals to adopt more precise, targeted coagulation monitoring, and TEG systems are emerging as the go-to technology in this shift toward patient-specific hemostatic therapy.

Can Thromboelastography Become the New Standard in Surgical and Emergency Medicine?

The clinical versatility of thromboelastography is positioning it as a new standard of care in surgical and emergency medicine environments where bleeding complications are common and time-critical decisions are essential. In cardiac and liver surgeries, where coagulopathies are often complex and multi-factorial, TEG provides the granularity needed to distinguish between consumptive and dilutional coagulopathy, enabling precise intervention. Its utility in managing anticoagulated patients-whether on warfarin, DOACs, or heparin-makes it a valuable tool in both preoperative screening and intraoperative monitoring. Emergency departments are also turning to TEG in the management of trauma patients, where massive transfusion protocols can be optimized based on TEG-guided insights, reducing both morbidity and mortality. Obstetric centers are using TEG to assess bleeding risk in cases of postpartum hemorrhage, especially in preeclampsia and HELLP syndrome. Meanwhile, intensive care units (ICUs) are incorporating TEG for ongoing coagulation assessment in patients with sepsis, disseminated intravascular coagulation (DIC), or COVID-19-associated coagulopathy. The widespread applicability across medical disciplines and the demand for faster, data-driven decisions are driving a shift toward real-time coagulation diagnostics powered by TEG.

What Technological Enhancements Are Expanding the Capabilities of Thromboelastography?

Recent advancements in thromboelastography technology are making the systems more user-friendly, accurate, and adaptable to various clinical settings. Modern TEG analyzers feature automated sample handling, touch-screen interfaces, and integrated quality controls, reducing technician error and enabling consistent results. Portable and point-of-care (POC) TEG systems are expanding access to real-time coagulation monitoring beyond tertiary hospitals into smaller surgical centers, ambulances, and field hospitals. Software upgrades now allow for advanced analytics, cloud-based data sharing, and integration into electronic health records (EHRs), ensuring that results can be interpreted quickly and used effectively in multidisciplinary care. Some systems offer cartridge-based testing, eliminating the need for manual pipetting and enhancing biosafety during infectious disease outbreaks. Manufacturers are also exploring multiplexed assays and biomarker integration to improve diagnostic specificity and guide anticoagulant reversal strategies. Coupled with increased clinical training and algorithm-based decision support tools, these enhancements are reducing the learning curve and helping clinicians incorporate TEG insights into real-time therapeutic decisions, thereby expanding its utility across increasingly diverse healthcare environments.

The Growth in the Thromboelastography Market Is Driven by Several Factors…

The rising adoption of thromboelastography is primarily driven by its growing clinical relevance in high-risk surgical specialties, trauma care, and critical illness management. The increasing global burden of cardiovascular disease, liver disorders, and trauma cases-particularly in emerging economies-is necessitating more precise tools for hemostasis assessment and transfusion management. Additionally, as surgical volumes rise and minimally invasive procedures become more complex, the need for accurate intraoperative coagulation monitoring is intensifying. Hospitals are under pressure to reduce blood product usage both for cost containment and to avoid transfusion-related complications, pushing demand for precision-guided transfusion strategies like those enabled by TEG. In parallel, the rising prevalence of anticoagulant therapy and complex coagulopathies in aging populations is creating a need for technologies that can accurately evaluate clotting status in real time. Point-of-care testing trends and the decentralization of diagnostic services are also expanding TEG adoption beyond large hospitals to ambulatory surgical centers and emergency response units. Technological advancements-such as automation, portability, and EHR integration-are enhancing usability and reducing operational barriers, while regulatory approvals and clinical guideline endorsements are reinforcing TEG’s value in modern clinical workflows. These converging dynamics across technology, healthcare delivery, and patient demographics are propelling the rapid growth of the global thromboelastography market.

SCOPE OF STUDY:

The report analyzes the Thromboelastography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen, Platelet Mapping); Application (Cardiopulmonary Bypass, Liver Surgery, Trauma Surgery, Obstetrics); End-User (Hospitals, Blood Banks, Academic Institutes, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• 5-Diagnostics GmbH
• Bio-Zircon
• Biomart
• Chongqing Dingrun
• Chongqing Nanfang
• Diagnostica Stago
• Framar Hemologix Srl
• Guizhou Jinjiu Biotech
• Haemonetics Corporation
• HemaCore LLC
• Instrumentation Laboratory (Werfen)
• Lepu Medical Technology
• Medcaptain Medical Technology
• Medirox AB
• Render Biotech Co., Ltd.
• Sienco, Inc.
• SYCOmed e.K.
• Ud-Bio
• WerfenLife
• WITEYE

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Thromboelastography - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increased Surgical Procedures Drive Demand for Real-Time Hemostasis Testing
  • Rise in Trauma Cases and Critical Care Settings Strengthens Product Utilization
  • Rapid Adoption in Cardiovascular Surgery Expands Market Footprint
  • Personalized Medicine Initiatives Propel Growth of Point-of-Care Coagulation Analysis
  • Shift Toward Comprehensive Coagulation Profiling Drives Technological Innovation
  • Growing Use in Postpartum Hemorrhage and Liver Transplant Cases Broadens Applications
  • Clinical Evidence Supporting Improved Outcomes Spurs Adoption
  • Integration with Hospital EMR Systems Enhances Workflow Efficiency
  • Expanding Role in Anticoagulant Monitoring Increases Device Penetration
  • Training and Awareness Initiatives Drive Usage in Low-Penetration Markets
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Thromboelastography Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Thromboelastography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Rapid TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Rapid TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Rapid TEG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Native TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Native TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Native TEG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Heparinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Heparinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Heparinase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Functional Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Functional Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Functional Fibrinogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Platelet Mapping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Platelet Mapping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Platelet Mapping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Obstetrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Obstetrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Obstetrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cardiopulmonary Bypass by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cardiopulmonary Bypass by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cardiopulmonary Bypass by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Liver Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Liver Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Liver Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Trauma Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Trauma Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Trauma Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• JAPAN
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• CHINA
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• EUROPE
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Thromboelastography by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• FRANCE
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• GERMANY
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Thromboelastography by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• INDIA
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 179: India Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Thromboelastography by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Thromboelastography by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
• AFRICA
  • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION